Form 4: BioMarin Executive Charles Greg Guyer Reports Stock Transactions
SEC Form 4 Filing
EVP, Chief Technical Officer of BioMarin Pharmaceutical Inc., Charles Greg Guyer, reports acquisition of shares through the Employee Stock Purchase Plan and disposition of shares for tax purposes.
Summary
- Charles Greg Guyer, EVP, Chief Technical Officer of BioMarin Pharmaceutical Inc., filed a Form 4.
- On April 30, 2024, Guyer acquired 245 shares of common stock at a price of $68.646 per share through the Employee Stock Purchase Plan.
- On May 3, 2024, Guyer disposed of 4,440 shares of common stock at a price of $82.44 per share.
- Following these transactions, Guyer beneficially owns 74,132 shares of BioMarin Pharmaceutical Inc.
Sentiment
Score: 5
Explanation: The document is a routine filing of stock transactions by a company executive, with neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in beneficial ownership by a company executive.
Key Dates
| Date | Description |
|---|---|
| 04/30/2024 | Acquisition of 245 shares of common stock through Employee Stock Purchase Plan at $68.646 per share. |
| 05/03/2024 | Disposition of 4,440 shares of common stock at $82.44 per share. |
| 05/07/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.